Endocyte, Inc. ECYT
We initially took notice of ECYT on Monday morning just as the company announced it had completed a worldwide license for its prostate cancer treatment now moving into Phase-3 development.
The stock made a solid 130% rip from 1.63 to 3.75 that morning, but it was only just getting started. Yesterday morning the stock ran hard once again, reaching its peak at a new annual high of 6.55. That puts the total on our two-day observed increased of 302% while volume over the same period has been literally hundreds of times greater than the monthly average prior to Monday’s bombshell PR.
Tiffany & Co. TIF – Options Update
As we were just mentioning yesterday morning, we’ve been tracking the TIF 10/20 $92-93 Calls since the morning of September 28th. TIF stock has maintained its gradual ascent since that time, and with that, we’ve seen the potential gains made off of our ideas grow along with it.
The following ranges represent the lows from the 28th to the highs achieved during yesterday’s session:
$92 Calls – Range: 1.00-2.20 – Max Gain: 120%
$92.50 Calls – Range: .85-2.19 – Max Gain: 158%.
$93 Calls – Range: .83-2.15 – Max Gain: 159%
Cesca Therapeutics Inc. KOOL
After including KOOL in yesterday morning’s watchlist, we watched as the stock made a very nice intraday run on the chart with the help of some positive news.
The U.S. Patent and Trademark Office issued a Notice of Allowance on the company’s patent application for its proprietary method for separating target cells from blood, marrow, and other sources.
That prompted a solid boost from 3.96 to 6.44 on the day, marking an intraday push of 63% which was accompanied by the trading of 223X more shares than the monthly average!
CATB, RGSE, CAPR, ATNM, VKTX, MNKD, BIOP, HTBX